retatrutide available (RETA) – Research Peptide Retatrutide 20mg | Triple GIP/GLP-1/Glucagon

[1] 40:15 - The 600% Increase and What It Means Walker explains that for GLP-1 or CCK to suppress appetite, you need to get over fourfold from baseline -- a challenging threshold for nutritional supplements to reach

Retatrutide is a triple-agonist peptide targeting GLP-1 + GIP + glucagon receptors simultaneously the most pronounced weight-loss data from any metabolic peptide studied to date

COMBI: metformin 1000 mg BID + liraglutide 1.2 mg/day (COMBI: n = 11) [61]

Figure 2: Growing proportion of GLP - 1 users are taking the drugs for weight loss Figure 3: Weight management users differ from health management users The shift in these proportions is already happening